Addiction Treatment Starts Here



MAT and COVID-19 Webinar Series April 15, 2020



Webinar Reminders

- 1. Everyone is muted.
 - *****6 to **unmute**
 - *6 to **re-mute**
- 2. Use the chat box for questions and to share what you're working on.
- **3. This webinar is being recorded.** The slides and webinar recording will be emailed and posted to the ATSH program page.

Agenda

- Introductions
- Ask the Expert: Complex Cases and Remote Prescribing
- Virtual Groups
- Q&A
- Closing

ATSH COVID-19 Series

Joe Sepulveda, MD, ABPN, ABPM, FAPA, FASAM Family Health Centers of San Diego

- Adult Psychiatrist
- Assistant Medical Director

Team Perspectives on Virtual Visits:

- Chapa De Indian Health
- Fresno New Connections
- KCS Health Center



Ask the Expert!



Questions

- **Co-occurring diagnoses:** What are the considerations in prescribing for patients with co-occurring diagnoses or conditions, including:
 - SUD: Alcohol use, stimulant use, or patients who also use benzos?
 - Mental health diagnoses
 - Hepatitis C
- **Pain orphans:** How should we navigate OUD treatment options, including prescribing buprenorphine, for patients who are suddenly cut off from prescription opioids because that prescriber will no longer see them
- **Refills for non-adherent patients:** How can we manage telephone refills for patients with a history of being not consistently adherent (e.g., missed appts, early refill requests, etc.)? When should we bring that patient into the clinic, during COVID-19?
- **Patient history:** How should we handle telephone prescribing for brand new patients calls if that patient doesn't have a clearly confirmable history (e.g., nothing in CURES and no other collateral available)? We can't confirm the facts that we normally want to confirm.



Your questions: use the chat box or unmute your phone!



CENTER FOR CARE INNOVATIONS | 7

Virtual Group Visits



Virtual Group Visits





Chapa De Indian Health



Kylie Timmerman, BSN, RN, PHN, Nurse Case Manager for SUD

- ATSH:PC participant
- Rural clinic, located ~60 miles NE of Sacramento
- Two sites (Auburn, Grass Valley), both of which offer MAT
- 23,000 total patients: 8 xwaivered prescribers; 53 MAT patients (all buprenorphine)

- What technology platform are you using and how well does it work?
- What staff are involved the visits (e.g., staff roles and tasks to plan and conduct the group visits)?
- Describe the logistics of your outreach process (e.g., call or text patients, provide connection info, etc.)
- What technology challenges do patients encounter? How have you addressed them?
- How has the structure of your groups changed now that you do them virtually (e.g., facilitating, inviting patients to share their story, etc.)
- What recommendations do you have for clinics that want to start virtual groups?

Fresno New Connections



Cheryl Whittle, PhD, LCSW, Clinical Supervisor

- Outpatient drug and alcohol treatment program (ATSH:BH participant)
- Patients receive medications at a local pain management group (LAGS)
- 300 total patients: 2 xwaivered prescribers; 42 MAT patients (41 naltrexone, 1 buprenorphine)

- What technology platform are you using and how well does it work?
- What staff are involved the visits (e.g., staff roles and tasks to plan and conduct the group visits)?
- **Describe the logistics** of your outreach process (e.g., call or text patients, provide connection info, etc.)
- What technology challenges do patients encounter? How have you addressed them?
- How has the structure of your groups changed now that you do them virtually (e.g., facilitating, inviting patients to share their story, etc.)
- What recommendations do you have for clinics that want to start virtual groups?

KCS



Grace Xu, Managing Director

- KCS FQHC, located in Buena Park (Orange County)
- Participant in both cohorts of ATSH - primary care and behavioral health
- 3,200 total patients: 3 xwaivered prescribers; 41 patients on MAT (25 buprenorphine, 16 naltrexone)

- What technology platform are you using and how well does it work?
- What staff are involved the visits (e.g., staff roles and tasks to plan and conduct the group visits)?
- **Describe the logistics** of your outreach process (e.g., call or text patients, provide connection info, etc.)
- What technology challenges do patients encounter? How have you addressed them?
- How has the structure of your groups changed now that you do them virtually (e.g., facilitating, inviting patients to share their story, etc.)
- What recommendations do you have for clinics that want to start virtual groups?

Questions?



Additional Questions

- Email: Briana Harris-Mills briana@careinnovations.org
- Briana will triage your questions and share with the appropriate ATSH coach or team member



Appendix



CENTER FOR CARE INNOVATIONS | 15

Physician Support Line

Free Confidential Peer Support Line by Volunteer Psychiatrists for US Physician Colleagues during the COVID19 Pandemic

1-888-409-0141 NOW LIVE

7 days a week 8am - 12am EST

www.physiciansupportline.com



Federal Guidance and Resources

- <u>DEA guidance</u> on allowing prescriptions of buprenorphine to new and existing patients with OUD via telephone.
- SAMHSA <u>FAQ</u> on prescribing buprenorphine (see question 4, which indicates that new patients can be prescribed buprenorphine via telephone outside an OTP). FAQ released on March 19, 2020.
- SAMSHA <u>guidance on the application of 42 CFR Part 2</u> in a public health emergency (released March 19, 2020).
- SAMSHA <u>MAT resource page</u> including various guidance documents for OTPs. Also includes link to a <u>Virtual Recovery Resource</u> list.
- HHS <u>Health Information Privacy Page</u>, including a <u>notice</u> allowing for enforcement discretion for remote communications (e.g., allowing use of non-HIPAA compliant devices for telehealth).
- DEA COVID-19 Information Page
- Changes to <u>EMTALA regulations</u>, in light of the public health emergency (updated March 15, 2020).
- In a March 17, 2020 <u>news release</u>, CMS indicates that Medicare can pay for office, hospital and other visits furnished via telehealth starting March 6, 2020 and for the duration of the COVID-19 public health emergency.



California Guidance and Resources

- DHCS COVID-19 Response <u>landing page</u>
- DHCS guidance around Medi-Cal Payment for Telehealth and Virtual/Telephonic <u>Communications</u>. Released March 24, 2020.
- DHCS <u>Guidance to Medi-Cal Managed Care Plans</u> requiring plans to reimburse providers at the same rate regardless of whether a service is provided in person, via telehealth, or via telephone. Released March 18, 2020.
- CA Office of Health Information Integrity (CalOHII) <u>Disaster Response and Information</u> <u>Sharing during Emergencies</u>, including specific references to SUD and MAT data sharing (March 18, 2020).
- DHCS <u>guidance for behavioral health programs</u> on providing behavioral health services via telephone and telehealth, adapting oversight requirements, and access to prescription medications. Released March 14, 2020.
- DHCS <u>FAQ on Behavioral Health Services</u> in light of COVID-19, updated on March 13, 2020.
- California's "<u>One-Stop Coronavirus Website</u>" (not MAT specific)



California Bridge Program Materials

- <u>Slides</u> and <u>recording</u> from 60-minute webinar which reviews key steps for keeping patients and providers safe while providing MAT. Webinar recorded on March 18, 2020.
- Link to <u>legal analysis of four hypothetical scenarios</u> for prescribing buprenorphine during COVID-19, prepared for the Foundation for Opioid Response Efforts (March 19, 2020).
- CA Bridge example <u>MAT Patient Flyer</u> for COVID
- CA Bridge <u>Home Start Guide</u>, <u>Buprenorphine After Overdose</u>
- CA Bridge <u>COVID-19 information page</u> and resources

Harm Reduction + Telehealth

- Harm Reduction
 - Yale Program in Addiction Medicine: <u>Guidance for People Who Use</u> <u>Substances on COVID-19</u>, focusing on harm reduction strategies.
 - Harm Reduction Coalition's COVID-19 <u>Virtual Office Hours</u> (March 18, 2020).
 - Harm Reduction Coalition: <u>Syringe Services and Harm Reduction During</u> <u>COVID-19</u> (updated March 11, 2020) and <u>Safer Drug Use During the COVID-</u> <u>19 Outbreak</u> (updated March 11, 2020).
- Telehealth
 - The <u>California Telehealth Resource Center</u> provides <u>sample forms and</u> <u>guidelines</u> for implementing a telehealth program. It also recently updated its <u>Telehealth Reimbursement Guide</u>, which includes telehealth reimbursement policies for Medicare, Medi-Cal Fee-For-Service, and Managed Care.



Other COVID-19 Webinars

- Foundation for Opioid Response Efforts COVID-19 Series <u>slides and recording</u>
- California Primary Care Association: Weekly COVID-19 Webinars <u>Link to</u> registration and recording/slides.
- Health Management Associates (HMA): COVID-19 Resource Library <u>INFO AND</u>
 <u>RECORDINGS</u>
- California Medical Association (CMA): COVID-19 webinar series <u>SLIDES AND</u>
 <u>RECORDINGS</u>

